Change in hemolysis measures from baseline to day 28
| Change from baseline to day 28 . | Multiple dose for 28 d . | |||
|---|---|---|---|---|
| Voxelotor/placebo, mg/d | Placebo | 500 | 700 | 1000 |
| N | 10 | 10 | 12 | 6 |
| Hb, median (25th, 75th percentile), g/dL | −0.1 (−0.4, 0.4) | 0.4 (0.1, 0.7) | 0.7 (0.5, 1.0) | 0 (−0.4, 0.3) |
| Unconjugated bilirubin, median (25th, 75th percentile), % change | −3.6 (−25.9, 6.7) | −30.6 (−48.9, −15.4) | −42.6 (−44.4, −23.8) | −56.3 (−57.8, −47.1) |
| Percentage of reticulocytes, median (25th, 75th percentile), % change | 9.0 (−1.7, 13.7) | −31.2 (−48.9, −20.8) | −37.0 (−52.6, −4.5) | −49.9 (−64.3, −34.4) |
| LDH, median (25th, 75th percentile), % change | −6.6 (−16.8, −2.9) | −19.9 (−39.0, 6.2) | −12.0 (−30.2, −5.7) | −12.4 (−20.2, −12.1) |
| Sickled red cells, median (25th, 75th percentile), % change | 12.9 (−13.6, 12.9) | −56.4 (−70.2, −26.2) | −45.9 (−93.0, −6.0) | −45.7 (−57.9, 5.9) |
| Change from baseline to day 28 . | Multiple dose for 28 d . | |||
|---|---|---|---|---|
| Voxelotor/placebo, mg/d | Placebo | 500 | 700 | 1000 |
| N | 10 | 10 | 12 | 6 |
| Hb, median (25th, 75th percentile), g/dL | −0.1 (−0.4, 0.4) | 0.4 (0.1, 0.7) | 0.7 (0.5, 1.0) | 0 (−0.4, 0.3) |
| Unconjugated bilirubin, median (25th, 75th percentile), % change | −3.6 (−25.9, 6.7) | −30.6 (−48.9, −15.4) | −42.6 (−44.4, −23.8) | −56.3 (−57.8, −47.1) |
| Percentage of reticulocytes, median (25th, 75th percentile), % change | 9.0 (−1.7, 13.7) | −31.2 (−48.9, −20.8) | −37.0 (−52.6, −4.5) | −49.9 (−64.3, −34.4) |
| LDH, median (25th, 75th percentile), % change | −6.6 (−16.8, −2.9) | −19.9 (−39.0, 6.2) | −12.0 (−30.2, −5.7) | −12.4 (−20.2, −12.1) |
| Sickled red cells, median (25th, 75th percentile), % change | 12.9 (−13.6, 12.9) | −56.4 (−70.2, −26.2) | −45.9 (−93.0, −6.0) | −45.7 (−57.9, 5.9) |